Table 6.
Baseline blood analyses as predictors of follow-up HAQ score
Study details |
Predictor: Baseline ESR/CRP |
Predictor: Baseline RF/ACPA |
|||||
---|---|---|---|---|---|---|---|
Study | N | Analysis method | Associated with HAQ | Effect sizea | Associated with HAQ | Effect sizea | Adjusted for |
Multivariable analyses | |||||||
Humphreys [40] | 1995 | Generalised estimating equations analysis | – | – | ✗ (RF) | RF + vs. RF–: b –0.03 (–0.12, 0.05) | Age, gender, smoking status, polynomials of disease duration, year of recruitment |
✓ (ACPA) | ACPA+ vs. ACPA–: b 0.12 (0.02, 0.21) | ||||||
Malm [32] | 1387 | Logistic regression (HAQ cut-off = 0.75) | ✓ (ESR) | Per unit baseline ESR: | – | – | Age, gender, disease duration |
OR 1.01 (1.00, 1.01) | |||||||
Nair [30] | 1034 | Linear mixed model | – | – | ✗ (RF) | RF+ vs. RF–: | Age, gender, treatment, Sharp Score (van der Heijde modification), HAQ (t-1), DAS28, BMI |
Cohort 1 b 0.00, p = 0.99 | |||||||
Cohort 2 b 0.00, p = 0.90 | |||||||
Burr [50] | 640 | Logistic regression (HAQ cut-off = 1) | – | – | ✗ (ACPA) | Per unit baseline ACPA titre: | Baseline: age, gender, symptom duration, CRP, RF, HAQ, swollen joint count, tender joint count |
OR 1.00 (0.99, 1.01) | |||||||
Kroot [38] | 273 | Multivariable linear regression | – | – | ✓ (RF) | RF+ vs. RF–: | Age, gender, DAS28, HLA-DR4 gene, |
✗ (ACPA) | b 0.15, p < 0.05 | ||||||
ACPA+ vs. ACPA–: | |||||||
b 0.00, p = NS | |||||||
Combe [34] | 191 | Multivariable linear regression | ✓ (CRP)✓ (ESR) | Per unit baseline CRP: | – | – | Baseline: DAS, swollen joint count, tender joint count, HAQ, pain VAS |
b 0.01 (p < 0.01) | |||||||
Per unit baseline ESR: | |||||||
b 0.01 (p < 0.01) | |||||||
Bjork [49] | 189 | Projections to latent structure discriminant analysis (HAQ cut-off = 0.08) | ✗ (CRP) | Per unit baseline CRP: | – | – | Baseline: Age, gender, HAQ, grip force, SOFI-lower limb, walking speed, GAT, wellbeing, swollen joint count, SOFI-hand, tender joint count, PGA, pain, SOFI-upper limb |
✗ (ESR) | VIP 0.63 (“not important”) | ||||||
Per unit baseline ESR: | |||||||
VIP 0.49 (“not important”) | |||||||
Welsing [31] | 185 | General linear mixed model | – | – | ✓ (RF) | RF+ vs. RF–: | Baseline: age, sex; time-varying: Sharp score, squared Sharp score, DAS28 |
b 0.19 (0.03, 0.35) | |||||||
Lindqvist [54] | 183 | Stepwise logistic regression (HAQ cut-off = 1.0) | ✗ (ESR) | NS – coefficients and confidence intervals not reported | ✗ (RF) | NS – coefficients and confidence intervals not reported | Age, gender, genotype, HAQ, active joint count |
Verstappen [36] | 112 | Logistic regression (HAQ cut-off = 1) | ✗ (ESR) | Per unit baseline ESR: | – | – | Disease duration (natural log transformed) |
OR 1.00 (0.99, 1.02) | |||||||
Kuuliala [48] | 85 | Logistic regression (HAQ cut-off = 0.9) | – | – | ✗ (RF) | RF+ vs. RF–: | Age, gender, shared epitope, tertiles of soluble E-selectin |
OR 1.09 (0.33, 3.57) | |||||||
Benton [27] | 42 | Logistic regression (HAQ cut-off = 0.25) OR are the odds of being in the low HAQ group | ✗ (CRP) | Per unit baseline CRP: | – | – | Baseline: DAS, Ritchie index, HAQ, Sharp score; one year: DAS, Ritchie index, CRP, HAQ |
OR 0.99 (0.96, 1.03) | |||||||
Univariable analyses | |||||||
Koevoets [39] | 508 | Generalised estimating equations analysis | – | – | ✗ (RF) | RF+ vs. RF–: | – |
✗ (ACPA) | b –0.03 (–0.13, 0.08) | ||||||
ACPA+ vs. ACPA–: | |||||||
b –0.03 (–0.13, 0.07) | |||||||
Thyberg [55] | 251 | Chi-Square (HAQ cut-off=1) | – | – | ✗ (ACPA) | NS difference between proportion of ACPA+ patients between HAQ subgroups | – |
Jäntti [33] | 121 | Somers’ d | ✗ (ESR) | d = 0.12 (–0.04, 0.28) | ✗ (RF) | d = –0.18 (–0.62, 0.26) | – |
Contreras-Yanez [25] | 107 | Student’s t test Comparison groups: HAQ ≤ 0.2 at 5 years, yes/no | – | – | ✗ (RF) | Proportion baseline RF+: | – |
✗ (ACPA) | HAQ ≤ 0.2 82.1% | ||||||
HAQ > 0.2 82.6% | |||||||
p = 1.00 | |||||||
Proportion baseline ACPA+: | |||||||
HAQ ≤ 0.2 85.7% | |||||||
HAQ > 0.2 87.0% | |||||||
p=1.00 | |||||||
Woolf [58] | 88 | Calculated sensitivity and specificity of having HAQ > 0 at 5 years | ✓ (“raised CRP”) | Specificity/sensitivity: | ✓ (RF) | Specificity/sensitivity: | – |
93/74 | 64/37 | ||||||
Genevay [23] | 25 | Mann-Whitney | – | – | ✗ (RF) | Mean HAQ: | – |
RF+ 0.78 | |||||||
RF– 0.80 | |||||||
p = NS |